Growth-Hormone Signaling
Research focuses on stimulation of endogenous growth-hormone release
and related IGF-1 changes. These biological effects do not by
themselves establish clinical benefit.
![CJC-1295 WITHOUT DAC [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/cjc.jpg)
peptides
CJC-1295 WITHOUT DAC [10mg]
$60.00
CJC-1295 without DAC, also called Modified GRF 1-29, is a short-acting synthetic GHRH analog studied for its effects on growth-hormone signaling. Evidence for long-term benefits in healthy adults is limited. The 10 mg vial is a research product, not an FDA-approved medicine.
RESEARCH USE ONLY
Laboratory research
BATCH DOCUMENTATION
Not currently available
PRODUCT FORMAT
10 mg · Lyophilized powder
For laboratory research only. Not for human or animal consumption.
VIP Peptides · Research Compound
Modified GRF 1-29 Research Profile
CJC-1295 without DAC, also known as Modified GRF 1-29 or Mod GRF 1-29,
is a short-acting synthetic analog of growth hormone-releasing hormone
(GHRH). It is distinct from the longer-acting CJC-1295 version with DAC.
This profile covers the 10 mg research vial.
GHRH Analog
Compound type
Compound type
Short-Acting
Without DAC
Without DAC
10 mg
Vial quantity
Vial quantity
Research Use Only
Use classification
Use classification
Product Information
About Modified GRF 1-29
Modified GRF 1-29 is designed to resist rapid enzymatic breakdown.
It acts on GHRH receptors and is studied for its ability to stimulate
the pituitary’s release of growth hormone, which can affect
downstream IGF-1 levels.
The no-DAC form is described as short-acting, with an approximate
half-life of 30 minutes. It is intended to produce a more temporary
signal than the DAC version; this does not establish proven
health or performance benefits.
Research Overview
| Product | CJC-1295 without DAC |
|---|---|
| Also known as | Modified GRF 1-29 / Mod GRF 1-29 |
| Compound type | Short-acting GHRH analog |
| Vial quantity | 10 mg |
| Research focus | Growth-hormone signaling |
| Regulatory status | Not FDA-approved for any indication |
Research Areas
What Research Has Examined
Body Composition
Growth-hormone pathways are studied in relation to fat metabolism
and lean tissue. Meaningful body-composition benefits from the
no-DAC form in healthy adults have not been established.
Sleep & Recovery
Sleep quality, training recovery and connective-tissue effects are
discussed in research and community sources. Strong clinical
evidence for these outcomes with Modified GRF 1-29 is limited.
Combination Research
It is sometimes discussed alongside growth-hormone secretagogues
such as Ipamorelin. Claims of a stronger combined effect are not
established as a clinical outcome.
Evidence Limitations
What the Evidence Does Not Establish
Long-term outcome studies specifically on CJC-1295 without DAC in
healthy adults are limited. Research on related GHRH analogs or the
DAC version should not automatically be treated as evidence for this
no-DAC product.
Proposed effects on sleep, body composition, training recovery and
tissue quality are not proven clinical benefits of this research
vial.
Safety & Regulatory Status
Important Limitations
CJC-1295 without DAC is not FDA-approved for any indication. The FDA
identifies limited clinical safety data and potential concerns for
immunogenicity and peptide-related impurities in compounded CJC-1295
products. The FDA also reports serious adverse events associated with
CJC-1295, including increased heart rate and systemic vasodilatory
reactions.
CJC-1295 is prohibited under the WADA Prohibited List as a growth
hormone-releasing factor. The list applies in- and out-of-competition.
Reported side effects in the supplied source include transient flushing
or warmth, water retention, increased hunger, vivid dreams, headache,
joint stiffness and tingling. The available information does not
establish the safety of long-term use.
For laboratory research only. Not intended for human or animal
consumption, clinical use, diagnosis, treatment, cure, mitigation or
prevention of disease.
consumption, clinical use, diagnosis, treatment, cure, mitigation or
prevention of disease.
![GLP1S [30mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/glp1s-300x300.jpg)
![GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) [100mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/ghk-300x300.jpg)
![Ipamorelin [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/ipamorelin-300x300.jpg)
![NAD+ (oxidized nicotinamide adenine dinucleotide) [1000mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/nad-300x300.jpg)
Reviews
There are no reviews yet.